Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy



Status:Recruiting
Conditions:Ocular, Ocular, Diabetes
Therapuetic Areas:Endocrinology, Ophthalmology
Healthy:No
Age Range:18 - 100
Updated:4/6/2019
Start Date:January 2017
End Date:December 2020
Contact:Gulnar Hafiz, MD, MPH
Email:ghafiz1@jhmi.edu

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
In this study, markers of oxidative stress will be measured in the aqueous humour of
stargardt disease, age related macular degeneration and diabetic retinopathy patients
compared to controls.

People with Stargardt disease, age related macular degeneration (AMD) and diabetic
retinopathy (DR) have decrease in central vision from damage to photoreceptors. One of the
mechanisms causing damage is high levels of oxygen in the eye. This damage produces specific
biomarkers that can be measured in eye fluid (aqueous humor). In this study, these biomarkers
will be assessed in people with Stargardt disease, age related macular degeneration and
diabetic retinopathy, compared to controls.

Inclusion Criteria:

- Signed informed consent and authorization of use and disclosure of protected health
information

- Age at least 18 years

- For the study group, patients diagnosed with Stargardt disease, age related macular
degeneration and diabetic retinopathy by the investigators, based on clinical
phenotype

- For the control group, patients with no retinal disease undergoing cataract surgery
will be eligible.

Exclusion Criteria:

• None
We found this trial at
1
site
Wilmer Eye Institute
Baltimore, Maryland
Principal Investigator: Peter Campochiaro, MD
?
mi
from
Baltimore, MD
Click here to add this to my saved trials